Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies

• Main Authors: Lone Fjord-Larsen (Author), Annemette Thougaard (Author), Karen Malene Wegener (Author), Joan Christiansen (Author), Frank Larsen (Author), Lise Maj Schrøder-Hansen (Author), Marianne Kaarde (Author), Dorte Kornerup Ditlevsen (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Alpha-synuclein is a 15 kDa protein associated with neurodegenerative diseases such as Parkinson disease and multiple-system atrophy where pathological forms of alpha-synuclein aggregate and become neurotoxic. Here we describe the nonclinical program to support a first-in-human (FIH) single ascendin...